Physician profile
Calvin C Brown
NPI 1578761011
$15,197.28
in general payments reported to CMS, 2019-2025
23 companies · $731 in 2025
The $731 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $939 · 2020: $215 · 2021: $290 · 2022: $1,012 · 2023: $9,801 · 2024: $2,209 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,251 · Honoraria: $4,200 · Food and Beverage: $2,966 · Entertainment: $122 · Travel and Lodging: $102 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,250.50 |
| Honoraria | $4,200.00 |
| Food and Beverage | $2,966.03 |
| Entertainment | $122.22 |
| Travel and Lodging | $102.18 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $9,212.86 | 2022-2025 | Syfovre |
| Alimera Sciences, INC. | $2,078.08 | 2019-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $802.21 | 2019-2025 | Vabysmo, Susvimo |
| Abbvie INC. | $461.64 | 2022-2025 | Ozurdex, Durysta |
| Regeneron Healthcare Solutions, INC. | $424.04 | 2019-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $382.79 | 2020-2024 | Acthar |
| Eyepoint US, INC. | $329.42 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $257.66 | 2019-2021 | |
| Optos, INC. | $212.00 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Allergan, INC. | $182.36 | 2019-2021 | |
| Biogen, INC. | $179.48 | 2022-2023 | |
| Astellas Pharma US INC | $151.05 | 2023-2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.41 | 2019 | |
| Notal Vision, INC. | $89.22 | 2019 | |
| Dutch Ophthalmic, USA | $83.02 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $48.56 | 2021 | |
| Coherus Oncology, INC. | $48.12 | 2023-2024 | |
| Bausch & Lomb Americas INC. | $32.59 | 2022-2024 | Xiidra, Miebo |
| Spark Therapeutics, INC. | $30.84 | 2022 | |
| Ocular Therapeutix, INC. | $22.18 | 2023 | Dextenza |
| Harrow Eye, LLC | $21.53 | 2023 | Iheezo |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.